


## ARQ 621

Cat. No.:	HY-16062
CAS No.:	1095253-39-6
Molecular Formula:	C <sub>28</sub> H <sub>24</sub> Cl <sub>2</sub> FN <sub>5</sub> O <sub>2</sub>
Molecular Weight:	552.43
Target:	Kinesin
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton
Storage:	-20°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 110 mg/mL (199.12 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	1.8102 mL	9.0509 mL	18.1018 mL
5 mM	0.3620 mL	1.8102 mL	3.6204 mL
10 mM	0.1810 mL	0.9051 mL	1.8102 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

ARQ 621 is an allosteric, potent and selective inhibitor of Eg5, a microtubule-based ATPase motor protein involved in cell division. Anti-tumor activity<sup>[1]</sup>. ARQ 621 is a kinesin inhibitor<sup>[2]</sup>. ARQ 621 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAC) with molecules containing Azide groups.

#### IC<sub>50</sub> & Target

Eg5

#### In Vitro

Over-expression of Eg5 causes genomic instability and tumor formation in mice; therefore, Eg5 is a potential anti-cancer target<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. L. C. Chen, et al. First-in-human study with ARQ 621, a novel inhibitor of Eg5: Final results from the solid tumors cohort. *J Clin Oncol*. 2011, May (20): 3076-3076.
- [2]. Lindsay S Roberts, et al. Mapping Novel Metabolic Nodes Targeted by Anti-Cancer Drugs that Impair Triple-Negative Breast Cancer Pathogenicity. *ACS Chem Biol*. 2017

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA